Dr Lisette Nixon
Timau a rolau for Lisette Nixon
Cymrawd Ymchwil - Uwch Reolwr Treial mewn Tiwmorau Solid
Trosolwg
Ymunais ag Uned Treialon Canser Cymru fel Rheolwr Treial ym mis Medi 2006 i ddechrau fel rheolwr ar gyfer treial SCOPE 1. Yna dechreuais gydlynu Gweithgor Trosiadol WCTU a dod yn aelod o grŵp Sicrhau Ansawdd Treialon Radiotherapi NCRI. Deuthum hefyd yn Rheolwr Treial I-START. Cefais fy nyrchafu i rôl Uwch Reolwr Treial ym mis Gorffennaf 2010, gan ymgymryd â rheolaeth llinell o'r Rheolwyr Treial o fewn WCTU a hefyd daeth yn Rheolwr Treial ar gyfer ROCS. Erbyn hyn mae gennyf rôl weithredol wrth oruchwylio llawer o'r treialon ar bortffolio WCTU , yn enwedig meysydd yr ysgyfaint a gastroberfeddol. Rwyf wedi darparu rheolaeth treial tymor byr o SCALOP, NEOSCOPE a SCOPE2, ar hyn o bryd dim ond rheoli I-START.
Rwyf wedi datblygu arbenigedd penodol yw treialon Chemo-radiotherapi a Radiotherapi, ac erbyn hyn mae gen i rôl wrth ddatblygu'r treialon hyn. Yn ddiweddar, rwyf wedi cyflwyno ceisiadau am gyllid ar gyfer treialon ychwanegol yn y maes hwn.
Mae profiad ymchwil blaenorol yn cynnwys ymchwil labordy clinigol yn adran meddygaeth anadlol Prifysgol Caerdydd, yn enwedig yn Ffibrosis Systig a COPD. Treuliais hefyd nifer o flynyddoedd yn profi endidau cemegol newydd fel ffarmacolegydd cynorthwyol yn y diwydiant fferyllol.
Mae gen i BSc mewn Ffarmacoleg, PhD mewn meddygaeth resbiradol/bioleg celloedd, a TAR (PCET) gyda phrofiad o addysgu mewn addysg uwch.
Cyhoeddiad
2026
- Morgan, R. D. et al., 2026. Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. EClinicalMedicine 96 104012. (10.1016/j.eclinm.2026.104012)
- Jones, S. E. et al. 2026. PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases. Pleura and Peritoneum (10.1515/pp-2025-0023)
- Wallis, L. et al., 2026. The QuinteT recruitment intervention and its role in oncology randomised controlled trials [Editorial]. Clinical Oncology 49 103976. (10.1016/j.clon.2025.103976)
2025
- Ibrahim, H. et al., 2025. ColoCap: determining the diagnostic accuracy of colon capsule endoscopy compared with standard colonoscopy in patients at risk of colorectal disease – a study protocol. BMJ Open 15 (9) e104661. (10.1136/bmjopen-2025-104661)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
2024
- Ajakaiye, A. et al., 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting Dublin, Ireland 16-18 October 2024. Vol. 34.BMJ Publishing Group. , pp.A350-A351. (10.1136/ijgc-2024-IGCS.611)
- O’Hara, J. T. et al., 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150 (11), pp.1002-1011. (10.1001/jamaoto.2024.3371)
- Holland-Hart, D. et al. 2024. The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. BMJ Open 14 (9) e076394. (10.1136/bmjopen-2023-076394)
2023
- Jones, S. E. F. et al. 2023. Launching the PICCOS trial: PIPAC in cancers of the colon, ovary and stomach. Presented at: European Society of Gynaecological Society Congress Istanbul, Turkey 28 September - 01 October 2023. BMJ Publishing Group(10.1136/ijgc-2023-ESGO.690)
- Mukherjee, S. et al., 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61 102059. (10.1016/j.eclinm.2023.102059)
2022
- Fennell, D. A. et al., 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52 101595. (10.1016/j.eclinm.2022.101595)
- Fennell, D. A. et al., 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48 101432. (10.1016/j.eclinm.2022.101432)
2021
- Mukherjee, S. et al., 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153 , pp.153-161. (10.1016/j.ejca.2021.05.020)
- Adamson, D. et al., 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6 (4), pp.292-303. (10.1016/S2468-1253(21)00004-2)
2018
- Lester, J. F. et al. 2018. Initial results of the phase ib/II, I-START trial: Isotoxic accelerated radiotherapy for the treatment of stage II-IIIb NSCLC. [Meeting Abstract}. Journal of Clinical Oncology 36 (15_Sup) e20551. (10.1200/JCO.2018.36.15_suppl.e20551)
2017
- Wills, L. et al., 2017. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiation Oncology 12 (1) 179. (10.1186/s13014-017-0916-7)
- Svobodova, M. et al. 2017. Optimising trial recruitment with well-designed screening log: experiences from the ROCS study [Abstract]. Trials 18 (S1), pp.93-94. (10.1186/s13063-017-1902-y)
2016
- Fokas, E. et al., 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120 (2), pp.212-216. (10.1016/j.radonc.2016.07.002)
- Gwynne, S. et al., 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89 20160020. (10.1259/bjr.20160020)
- Fokas, E. et al., 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?. Annals of Oncology 27 (sup. 2), pp.ii64.3-ii65. (10.1093/annonc/mdw199.214)
2015
- Fokas, E. et al., 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117 (3), pp.432-437. (10.1016/j.radonc.2015.08.026)
- Rees, J. et al., 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113 (4), pp.603-610. (10.1038/bjc.2015.258)
2014
- Adamson, D. et al., 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15 402. (10.1186/1745-6215-15-402)
2013
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87 (2), pp.S306. (10.1016/j.ijrobp.2013.06.804)
- Mukherjee, S. et al., 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31 (4) 230.
2012
- Gwynne, S. H. et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84 (4), pp.1037-1042. (10.1016/j.ijrobp.2012.01.094)
- Lester, J. F. et al., 2012. 156 The I-START trial: ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer [Abstract]. Lung Cancer 75 (S1), pp.S51. (10.1016/S0169-5002(12)70157-5)
2011
- Hurt, C. N. et al. 2011. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 11 (1), pp.466. (10.1186/1471-2407-11-466)
- Gwynne, S. et al., 2011. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: A United Kingdom definitive chemoradiotherapy trial for esophageal cancer. International Journal of Radiation Oncology - Biology - Physics 81 (2), pp.S67-S68. (10.1016/j.ijrobp.2011.06.135)
2009
- Nixon, L. S. et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21 (3), pp.255-255. (10.1016/j.clon.2009.01.001,)
2004
- Bolton, C. E. et al. 2004. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 170 (12), pp.1286-1293. (10.1164/rccm.200406-754OC)
2003
- Nixon, L. S. 2003. Neutrophil function in patients with cystic fibrosis and chronic pulmonary infection.. PhD Thesis , Cardiff University.
2002
- Ionescu, A. et al. 2002. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. American journal of respiratory and critical care medicine 165 (4), pp.495-500.
2000
- Ionescu, A. A. et al., 2000. Bone density, body composition, and inflammatory status in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine 162 (3), pp.789-794. (10.1164/ajrccm.162.3.9910118)
1999
- Abou-Hatab, K. et al., 1999. Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment. European Journal of Clinical Pharmacology 54 , pp.937–941. (10.1007/s002280050578)
Cynadleddau
- Ajakaiye, A. et al., 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting Dublin, Ireland 16-18 October 2024. Vol. 34.BMJ Publishing Group. , pp.A350-A351. (10.1136/ijgc-2024-IGCS.611)
- Jones, S. E. F. et al. 2023. Launching the PICCOS trial: PIPAC in cancers of the colon, ovary and stomach. Presented at: European Society of Gynaecological Society Congress Istanbul, Turkey 28 September - 01 October 2023. BMJ Publishing Group(10.1136/ijgc-2023-ESGO.690)
Erthyglau
- Morgan, R. D. et al., 2026. Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. EClinicalMedicine 96 104012. (10.1016/j.eclinm.2026.104012)
- Jones, S. E. et al. 2026. PICCOS: study protocol for pressurised intraperitoneal aerosolised chemotherapy (PIPAC) in the management of cancers of the colon, ovary and stomach: a randomised controlled, phase II trial of efficacy in peritoneal metastases. Pleura and Peritoneum (10.1515/pp-2025-0023)
- Wallis, L. et al., 2026. The QuinteT recruitment intervention and its role in oncology randomised controlled trials [Editorial]. Clinical Oncology 49 103976. (10.1016/j.clon.2025.103976)
- Ibrahim, H. et al., 2025. ColoCap: determining the diagnostic accuracy of colon capsule endoscopy compared with standard colonoscopy in patients at risk of colorectal disease – a study protocol. BMJ Open 15 (9) e104661. (10.1136/bmjopen-2025-104661)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
- O’Hara, J. T. et al., 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150 (11), pp.1002-1011. (10.1001/jamaoto.2024.3371)
- Holland-Hart, D. et al. 2024. The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. BMJ Open 14 (9) e076394. (10.1136/bmjopen-2023-076394)
- Mukherjee, S. et al., 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61 102059. (10.1016/j.eclinm.2023.102059)
- Fennell, D. A. et al., 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52 101595. (10.1016/j.eclinm.2022.101595)
- Fennell, D. A. et al., 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48 101432. (10.1016/j.eclinm.2022.101432)
- Mukherjee, S. et al., 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153 , pp.153-161. (10.1016/j.ejca.2021.05.020)
- Adamson, D. et al., 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6 (4), pp.292-303. (10.1016/S2468-1253(21)00004-2)
- Lester, J. F. et al. 2018. Initial results of the phase ib/II, I-START trial: Isotoxic accelerated radiotherapy for the treatment of stage II-IIIb NSCLC. [Meeting Abstract}. Journal of Clinical Oncology 36 (15_Sup) e20551. (10.1200/JCO.2018.36.15_suppl.e20551)
- Wills, L. et al., 2017. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiation Oncology 12 (1) 179. (10.1186/s13014-017-0916-7)
- Svobodova, M. et al. 2017. Optimising trial recruitment with well-designed screening log: experiences from the ROCS study [Abstract]. Trials 18 (S1), pp.93-94. (10.1186/s13063-017-1902-y)
- Fokas, E. et al., 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120 (2), pp.212-216. (10.1016/j.radonc.2016.07.002)
- Gwynne, S. et al., 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89 20160020. (10.1259/bjr.20160020)
- Fokas, E. et al., 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?. Annals of Oncology 27 (sup. 2), pp.ii64.3-ii65. (10.1093/annonc/mdw199.214)
- Fokas, E. et al., 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117 (3), pp.432-437. (10.1016/j.radonc.2015.08.026)
- Rees, J. et al., 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113 (4), pp.603-610. (10.1038/bjc.2015.258)
- Adamson, D. et al., 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15 402. (10.1186/1745-6215-15-402)
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87 (2), pp.S306. (10.1016/j.ijrobp.2013.06.804)
- Mukherjee, S. et al., 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31 (4) 230.
- Gwynne, S. H. et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84 (4), pp.1037-1042. (10.1016/j.ijrobp.2012.01.094)
- Lester, J. F. et al., 2012. 156 The I-START trial: ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer [Abstract]. Lung Cancer 75 (S1), pp.S51. (10.1016/S0169-5002(12)70157-5)
- Hurt, C. N. et al. 2011. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 11 (1), pp.466. (10.1186/1471-2407-11-466)
- Gwynne, S. et al., 2011. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: A United Kingdom definitive chemoradiotherapy trial for esophageal cancer. International Journal of Radiation Oncology - Biology - Physics 81 (2), pp.S67-S68. (10.1016/j.ijrobp.2011.06.135)
- Nixon, L. S. et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21 (3), pp.255-255. (10.1016/j.clon.2009.01.001,)
- Bolton, C. E. et al. 2004. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 170 (12), pp.1286-1293. (10.1164/rccm.200406-754OC)
- Ionescu, A. et al. 2002. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. American journal of respiratory and critical care medicine 165 (4), pp.495-500.
- Ionescu, A. A. et al., 2000. Bone density, body composition, and inflammatory status in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine 162 (3), pp.789-794. (10.1164/ajrccm.162.3.9910118)
- Abou-Hatab, K. et al., 1999. Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment. European Journal of Clinical Pharmacology 54 , pp.937–941. (10.1007/s002280050578)
Gosodiad
- Nixon, L. S. 2003. Neutrophil function in patients with cystic fibrosis and chronic pulmonary infection.. PhD Thesis , Cardiff University.
Bywgraffiad
Addysg a Chymwysterau
2006: TAR / Cert Ed (PCET) (Sefydliad Prifysgol Cymru Caerdydd)
2004: Swyddogaeth Neutrophil PhD mewn cleifion â ffibrosis systig a haint cronig yr ysgyfaint. (Prifysgol Caerdydd)
1992: BSc (Anrh) (Ffarmacoleg) (Prifysgol Dwyrain Llundain)
1989: HNC (Bioleg Gymhwysol) (Prifysgol Swydd Hertford)
Trosolwg Gyrfa
Uwch Reolwr Treial (Gorffennaf 2010 hyd yn hyn), Uned Treialon Canser Cymru, Canolfan Ymchwil Treialon
Rheolwr Treial (Medi 2006 i Fehefin 2010), Uned Treialon Canser Cymru.
Cydymaith Ymchwil (Tachwedd 1992 i Fedi 2006), Adran Meddygaeth Anadlol, Prifysgol Caerdydd.
Darlithydd (achlysurol, rhan-amser) Gwyddor Biofeddygol (Medi 2005 i Fawrth 08), Sefydliad Prifysgol Cymru Caerdydd
Darlithydd Cyswllt, Y Brifysgol Agored. SK121: Deall clefyd cardiofasgwlaidd (Medi 2007 i Hydref 2010); SDK125: Cyflwyniad i Astudiaethau Gofal Iechyd (Medi 2008 i Fehefin 2015)
Ffarmacolegydd cynorthwyol, Glaxo Group Research (GSK bellach), (Tachwedd 1987 i Octover 1992)
Aelodaethau proffesiynol
Cymdeithas Imiwnoleg Prydain, aelod 14311, 1997